Award Number: DAMD17-02-1-0452

TITLE: Cyclin E, A Powerful Predictor of Survival in Breast Cancer-A Prospective Study

PRINCIPAL INVESTIGATOR: Khandan Keyomarsi, Ph.D.

CONTRACTING ORGANIZATION: The University of Texas MD Anderson Cancer Center Houston, TX 77030

REPORT DATE: June 2004,

TYPE OF REPORT: Annual

MD Anderson Cancer Center Houston, TX 77030

20060309 104

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

Delengend public bit addition is at maked in the provide public bit of the addition of the of the addit addition of the addition of the addition of	R	EPORT DO	CUMENTATIO	N PAGE		Form Approved OMB No. 0704-0188
Bit State is bears the overlation and the state is any enable i	ublic reporting burden for this c ata needed, and completing and his burden to Department of Def	collection of information is d reviewing this collection fense. Washington Head	s estimated to average 1 hour per re n of information. Send comments re quarters Services. Directorate for Ir	esponse, including the time for review egarding this burden estimate or any (formation Operations and Reports (0	other aspect of this co 704-0188), 1215 Jeffe	hing existing data sources, gathering and maintaining the llection of information, including suggestions for reducing rson Davis Hichway, Suite 1204, Arlington, VA 22202-
REPORT PATE 2. REPORT TYPE 3. DATES COURED 1.06-2004 Annual 1.Jun 2003 - 31 May 2004 TTTLE AND SUBTITLE 5. CONTRACT NUMBER iyclin E, A Powerful Predictor of Survival in Breast Cancer-A Prospective Study 6. GRANT NUMBER .AUTHOR(S) 6. CONTRACT NUMBER chandan Keyomarsi, Ph.D. 5. TASK NUMBER .PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 5. TASK NUMBER PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER 5. TASK NUMBER IOD Anderson Cancer Center 5. WORK UNIT NUMBER IOD Anderson Cancer Center 10. SPONSOR/MONITOR'S ACRONYM(S) I.S. Army Medical Research and Materiel Command 10. SPONSOR/MONITOR'S ACRONYM(S) I.S. Army Medical Research and Materiel Command 11. SPONSOR/MONITOR'S ACRONYM(S) I.S. Army Medical Research and Materiel Command 11. SPONSOR/MONITOR'S ACRONYM(S) I.S. DISTRIBUTION / AVAILABILITY STATEMENT 11. SPONSOR/MONITOR'S ACRONYM(S)	302. Respondents should be a	ware that notwithstandin	g any other provision of law, no per	son shall be subject to any penalty for	failing to comply with	a collection of information if it does not display a currently
TITLE AND SUBTITLE 50. CONTRACT NUMBER cyclin E, A Powerful Predictor of Survival in Breast Cancer-A Prospective Study 50. GRANT NUMBER cyclin E, A Powerful Predictor of Survival in Breast Cancer-A Prospective Study 50. GRANT NUMBER AUTHOR(S) 54. PROJECT NUMBER Authors (S) 54. PROJECT NUMBER Chandan Keyomarsi, Ph.D. 56. TASK NUMBER PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 51. WORK UNIT NUMBER The University of Texas 54. PROSORING / MONTORING AGENCY NAME(S) AND ADDRESS(ES) S. Army Medical Research and Materiel Command 10. SPONSOR/MONITOR'S ACRONYM(S) Sy Chorson Random Materiel Command 11. SPONSOR/MONITOR'S ACRONYM(S) S. Army Medical Research and Materiel Command 11. SPONSOR/MONITOR'S REPORT S. Mary Medical Research and Materiel Command 11. SPONSOR/MONITOR'S REPORT S. Mary Medical Research and Materiel Command 11. SPONSOR/MONITOR'S REPORT S. JUSTRIBUTION / AVAILABILITY STATEMENT 11. SPONSOR/MONITOR'S REPORT S. SUPPLEMENTARY NOTES 3. SUPPLEMENTARY NOTES A ABSTRACT Near Structure (S) Structure (REPORT DATE				3. D	ATES COVERED
yedin E, A Powerful Predictor of Survival in Breest Cancer-A Prospective Study St. GRANT NUMBER DAMD17-02-1-0452 Sc. PROGRAM ELEMENT NUMBER AUTHOR(S) Sd. PROJECT NUMBER Sd. PROJECT NUMBER Sd. PROJECT NUMBER Sd. PROJECT NUMBER Sd. WORK UNIT NUMBER PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) S. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) S. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) S. Army Medical Research and Materiel Command ord Detrick, Maryland 21702-5012 S. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) S. SAMP Medical Research and Materiel Command ord Detrick, Maryland 21702-5012 S. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited S. SUPPLEMENTARY NOTES 4 ABSTRACT ABSTRACT ABSTRACT IS a prognostic marker for stage I and II breast cancer in a PROSPECTIVE stand, 20001), Our hypothesis Int dysregulation of cyclin E, a positive cell cycle regulator at the G1 to S transition, may affect the biological behavior f breast cancer. In a retrospective analysis of tumor specimens from 395 breast cancer patients, We found that Stard Systemicitation of cyclin E, a positive cell cycle regulator at the G1 to S transition, may affect the biological behavior f breast cancer. In a retrospective and yes in prognostic indicator of outcome in arry stage breast cancer death garalises of whether patients had lymph node-negative disease or lymph node-positive disease or lowed that Unor samples, formation or whether patients in the ST to prognostic indicator of outcome in arry stage breast cancer. Sectional yes with the expension of key cyclic E protocol with hey develop an immunchistochemical (HC) assay for specifically detecting the LMVV forms of cyclin E in Breast Cancer. We stransectively confirm cyclin E provession correlates with poor outcome, clinicians can more appropriately tailor aggressive respectively confirm cyclin E, tow molecular weight Kester Texts KepPT b ABSTRACT b	1-06-2004		Annual			
AUTHOR(S) DAMD17-02-1-0452 .AUTHOR(S) 5d. PROJECT NUMBER (handan Keyomarsi, Ph.D. 5d. PROJECT NUMBER FERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 6. TASK NUMBER FERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER 6f. WORK UNIT NUMBER BOALD Anderson Cancer Center NUMBER IO Anderson Cancer Center 10. SPONSOR/MONITOR'S ACROWYM(S) I.S. Army Medical Research and Materiel Command 10. SPONSOR/MONITOR'S ACROWYM(S) S. Army Medical Research and Materiel Command 11. SPONSOR/MONITOR'S ACROWYM(S) S. DETRIBUTION / AVAILABILITY STATEMENT 11. SPONSOR/MONITOR'S ACROWYM(S) S. DUPPLEMENTARY NOTES 3. SUPPLEMENTARY NOTES ABSTRACT In attrospective analysis of tumor specimens from 395 breast cancer patients, we found that werexpression of cyclin E is a powerful prognosic indicator of outcome in early stage breast cancer. Specifically detailed isease of (70.0001). Our hypothesis is that dyruph node-positive disease or (70.0001). Our hypothesis is that dyrequilation of cyclin E is a powerful prognosic indicator of outcome in early Stage breast cancer. Specifically detailed iseases of (70.0001). Our hypothesis is that dyrequilation of cyclin E is a powerful prognosic indicator of outcome in early Stage breast cancer. Specifically detailed iseases of (70.0001). Our hypothesis is that dyrequilation divide methor patient and in the expression of key cell cycle regulators in fras	TITLE AND SUBTITL	E		• •	5a.	CONTRACT NUMBER
AUTHOR(6) 5c. PROGRAM ELEMENT NUMBER AUTHOR(5) 5d. PROJECT NUMBER ihandan Keyomarsi, Ph.D. 5e. TASK NUMBER IPERFORMING ORGANIZATION NAME(5) AND ADDRESS(ES) 5e. TASK NUMBER ihe University of Texas 5e. PERFORMING ORGANIZATION REPORT ID Anderson Cancer Center 50. IOUSION, TX 77030 5. SPONSORING / MONITORING AGENCY NAME(5) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(5) I.S. Army Medical Research and Materiel Command 10. SPONSOR/MONITOR'S ACRONYM(5) Ort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S ACRONYM(5) I.D. SUPPLEMENTARY NOTES 11. SPONSOR/MONITOR'S ACRONYM(5) 2. DISTRIBUTION / AVAILABILITY STATEMENT NUMBER(5) ABSTRACT ABSTRACT ABSTRACT NUMBER for Supported for Public Release, Distribution Unlimited 3. SUPPLEMENTARY NOTES 11. SPONSOR/MONITOR'S acrony sequences from 395 breast cancer, patients, we found that werexpression of toryclin E protein and its LMW isoforms was a very strong predictor of breast cancer. death gearalless of tymp node-positive disease or (pm)	volin F A Powerfu	al Predictor of S	Survival in Breast Car	icer-A Prospective Stu		
AUTHOR(6) AUTHOR(5) AUTHOR(5) AUTHOR(6)	, , , , , , , , , , , , , , , , , , ,				DA	
ihandan Keyomarsi, Ph.D. 5e. TASK NUMBER FERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 6. WORK UNIT NUMBER he University of Texas 8. PERFORMING ORGANIZATION REPORT ID Anderson Cancer Center 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) S. Somy Medical Research and Materiel Command 10. SPONSOR/MONITOR'S ACRONYM(S) 11. SPONSOR/MONITOR'S ACRONYM(S) S. Army Medical Research and Materiel Command 11. SPONSOR/MONITOR'S ACRONYM(S) 11. SPONSOR/MONITOR'S ACRONYM(S) S. DISTRIBUTION / AVAILABILITY STATEMENT NUMBER(S) 11. SPONSOR/MONITOR'S ACRONYM(S) S. UPPLEMENTARY NOTES 3. SUPPLEMENTARY NOTES 11. SPONSOR/MONITOR'S acroches 4. ABSTRACT Number Statistic Command indicator of outcome in early stage breast cancer Apteriations in expression of cyclin E, a positive cell cycle regulator at the G1 to S transition, may affect the biological behavior for breast cancer. In a refrospectify by clin E, a positive cell cycle regulators from 395 breast cancer Appendix we will: use cyclin E antibody as a prognostic marker for stage I and II breast cancer in a PROSPECTIVE study. 2: examine the gardless of whether patients had lymph node-negative disease or lymph node-positive disease (p < 0.0001). Our hypothesis is that dysregulation of cyclin E is a powerful prognostic indicator of outcome in early stage breast cancer. Specifically we will: L use cyclin E antibody as a prognostic marker for stage I and II breast cancer in a PROSPECTIVE study. 2: examine the gardless of whether patients had					50.	PROGRAM ELEMENT NOMBER
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) he University of Texas D Anderson Cancer Center louston, TX, 77030 S. Army Medical Research and Materiel Command ort Detrick, Maryland 21702-5012 S. Army Medical Research and Materiel Command ort Detrick, Maryland 21702-5012 Distribution / AVAILABILITY STATEMENT NUMBER(S) 2. DISTRIBUTION / AVAILABILITY STATEMENT NUMBER(S) 3. SUPPLEMENTARY NOTES 4. ABSTRACT Use cyclin E androxec the subject of the full-length cyclin E, a positive cell cycle regulator at the G1 to S transition, may affect the biological behavior if breast cancer. In a retrospective analysis of turnor specimens from 395 breast cancer patients, we found that verexpression of the full-length cyclin E, protein and its LIW isoforms was a very strong predictor of breast cancer death and signalized of the full-length cyclin E protein and its LIW isoforms was a very strong predictor of breast cancer check that dysregulation of cyclin E is a governity protein and its LIW isoforms was a very strong predictor of breast cancer check the associated activity and its immune-complex formation with key cell cycle regulators in freshly resected turnor samples with the expression of key cell and its pression correlates with poor outcome, clinicians can more appropriately tailor aggressive systemic treatment to those at greatest risk for systemic metastases (5. SUBJECT TERMS Prospective study, cell cycle, cyclin E, low molecular weight (16. SECURITY CLASSIFICATION OF:	AUTHOR(S)				5d.	PROJECT NUMBER
St. WORK UNIT NUMBER Set WORK UNIT NU	handan Keyomars	si, Ph.D.			5e.	TASK NUMBER
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER the University of Texas ID Anderson Cancer Center louston, TX 77030 8. PERFORMING ORGANIZATION REPORT NUMBER S.S. Army Medical Research and Materiel Command ort Detrick, Maryland 21702-5012 10. SPONSOR/MONITOR'S ACRONYM(S) 2. DISTRIBUTION / AVAILABILITY STATEMENT kpproved for Public Release; Distribution Unlimited 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 3. SUPPLEMENTARY NOTES 4. ABSTRACT 4. ABSTRACT berrations in expression of cyclin E, a positive cell cycle regulator at the G1 to S transition, may affect the biological behavior of breast cancer. In a retrospective analysis of tumor specimens from 395 breast cancer patients, we found that werexpression of the full-length cyclin E protein and its LMW isoforms was a very strong predictor of breast cancer death egardless of whether patients had ymph node-negative disease or lymph node-positive disease (0.0,0001), Our hypothesis is that dysregulation of cyclin E is a powerful prognostic indicator of outcome in early stage breast cancer. Specifically we will: I: use cyclin E asticoted activity and its immune-complex formation with key cell cycle regulators in freshly resected tumor samples, and 3: develop an immunohistochemical (IHC) assay for specifically detecting the LMW forms of cyclin E is reast cancer. We prospectively confirm cyclin E overexpression correlates with poor outcome, cliniclans can more appropriately tailor aggressive systemic treatment to those at greatest risk for systemic metastases 16. SEQURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER NUSAMRMC 18. SEQURITY CLASSIFICATION OF:	•	•			55	
he University of Texas NUMBER he University of Texas Interface Jouston, TX 77030 Interface is PONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) Interface J.S. Army Medical Research and Materiel Command Interface fort Detrick, Maryland 21702-5012 Interface Interface Interface 2. DISTRIBUTION / AVAILABILITY STATEMENT NUMBER(s) 2. DISTRIBUTION / AVAILABILITY STATEMENT NUMBER(s) 3. SUPPLEMENTARY NOTES Interface 4. ABSTRACT ABSTRACT Apparted for Public Release; Distribution Unlimited Interface 3. SUPPLEMENTARY NOTES Interface 4. ABSTRACT ABSTRACT Apparted for Vublic Release; Distribution Unlimited Interface 3. SUPPLEMENTARY NOTES Interface 4. ABSTRACT ABSTRACT 4. ABSTRACT Interface 4. ABSTRACT						
10 Anderson Cancer Center iouston, TX 77030			E(S) AND ADDRESS(ES)			
Iouston, TX 77030 SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) J.S. Army Medical Research and Materiel Command fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S ACRONYM(S) 2. DISTRIBUTION / AVAILABILITY STATEMENT typproved for Public Release; Distribution Unlimited 3. SUPPLEMENTARY NOTES 4. ABSTRACT Aberrations in expression of cyclin E, a positive cell cycle regulator at the G1 to S transition, may affect the biological behavior for breast cancer. In a retrospective analysis of tumor specimens from 395 breast cancer patients, we found that verexpression of the full-length cyclin E protein and its LMW isoforms was a very strong predictor of breast cancer death egardless of whether patients had lymph node-negative disease or lymph node-positive disease (p <0.0001). Our hypothesis						
SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) S. Army Medical Research and Materiel Command ort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S ACRONYM(S) 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 2. DISTRIBUTION / AVAILABILITY STATEMENT (s) (s) 2. DISTRIBUTION / AVAILABILITY STATEMENT (s) (s) 2. DISTRIBUTION / AVAILABILITY STATEMENT (s)						
I.S. Army Medical Research and Materiel Command ort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 2. DISTRIBUTION / AVAILABILITY STATEMENT upproved for Public Release; Distribution Unlimited 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 3. SUPPLEMENTARY NOTES 3. SUPPLEMENTARY NOTES 4. ABSTRACT before the public Release; Distribution Unlimited 9. Strain and its LMW isoforms was a very strong predictor of breast cancer death egardless of whether patients had lymph node-negative disease or lymph node-positive disease (p < 0.0001). Our hypothesis is that dysregulation of cyclin E is a powerful prognostic indicator of outcome in early stage breast cancer. Specifically we will: : use cyclin E antibody as a prognostic marker for stage I and II breast cancer in a PROSPECTIVE study, 2: examine the york cyclin E astociated activity and its immune-complex formation with key cell cycle regulators in freshly resected tumor samples and 3: develop an immunohistochemical (IHC) assay for specifically detecting the LMW forms of cyclin E in Breast Cancer. We will correlate the cyclin E alterations in samples with the expression of key cell cycle regulators and clinical biomarkers. If we prospectively confirm cyclin E overspression correlates with poor outcome, clinicians can more appropriately tailor aggressive systemic treatment to those at greatest risk for systemic metastases 15. SUBJECT TERMS Prospective study, cell cycle, cyclin E, low molecular weight 16. SECURITY CLASSIFICATION OF: 	louston, TX 77030	<u>ַ</u>				
I.S. Army Medical Research and Materiel Command ort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 2. DISTRIBUTION / AVAILABILITY STATEMENT poproved for Public Release; Distribution Unlimited 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 3. SUPPLEMENTARY NOTES 3. SUPPLEMENTARY NOTES 4. ABSTRACT bebrations in expression of cyclin E, a positive cell cycle regulator at the G1 to S transition, may affect the biological behavior of breast cancer. In a retrospective analysis of tumor specimens from 395 breast cancer patients, we found that werexpression of the full-length cyclin E protein and its LMW isoforms was a very strong predictor of breast cancer death egardless of whether patients had lymph node-negative disease or lymph node-positive disease (p < 0.0001). Our hypothesis is that dysregulation of cyclin E is a powerful prognostic indicator of outcome in early stage breast cancer. Specifically we will: : use cyclin E antibody as a prognostic marker for stage I and II breast cancer in a PROSPECTIVE study, 2: examing the iypolin E associated activity and Its immune-complex formation with key cell cycle regulators in freshly resected tumor samples and 3: develop an immunohistochemical (IHC) assay for specifically detecting the LMW forms of cyclin E in Breast Cancer. We vill correlate the cyclin E alterations in samples with the expression of key cell cycle regulators and clinical biomarkers. If we prospectively confirm cyclin E overspression correlates with poor outcome, clinicians can more appropriately tailor aggressive systemic treatment to those at greatest risk for systemic metastases 5. SUBJECT TERMS Prospective study, cell cycle, cyclin E, low molecular weight 17. LIMITATION OF ABSTRACT NUMBER (include aree 18. NUMBER (include aree		·				
int Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 2. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 3. SUPPLEMENTARY NOTES 3. SUPPLEMENTARY NOTES 4. ABSTRACT Abstract of the provide in and its LMW isoforms was a very strong predictor of breast cancer death egardless of whether patients had lymph node-negative disease or lymph node-positive disease (p <0.0001). Our hypothesis is that dysregulation of cyclin E is a powerful prognostic indicator of outcome in early stage breast cancer. Specifically we will: use cyclin E antibody as a prognostic marker for stage I and II breast cancer in a PROSPECTIVE study, 2: examine the cyclin E associated activity and its immune-complex formation with key cell cycle regulators in freshly resected tumor samples, and 3: develop an immunohistochemical (IHC) assay for specifically detecting the LMW forms of cyclin E in Breast Cancer. We will correlate the cyclin E auterations in samples with the expression of key cell cycle regulators and clinical biomarkers. If we prospectively confirm cyclin E averexpression correlates with poor outcome, clinicians can more appropriately tailor aggressive systemic treatment to those at greatest risk for systemic metastases				SS(ES)	10.	SPONSOR/MONITOR'S ACRONYM(S)
11. SPONSOR/MONITOR'S REPORT NUMBER(S) 2. DISTRIBUTION / AVAILABILITY STATEMENT (sporoved for Public Release; Distribution Unlimited) 3. SUPPLEMENTARY NOTES 4. ABSTRACT (berrations in expression of cyclin E, a positive cell cycle regulator at the G1 to S transition, may affect the biological behavior of breast cancer. In a retrospective analysis of tumor specimens from 395 breast cancer patients, we found that werexpression of the full-length cyclin E protein and its LMW isoforms was a very strong predictor of breast cancer death egardless of whether patients had lymph node-negative disease or lymph node-positive disease (p <0.0001). Our hypothesis is that dysregulation of cyclin E is a powerful prognostic indicator of outcome in early stage breast cancer. Specifically we will: use cyclin E antibody as a prognostic marker for stage I and II breast cancer in a PROSPECTIVE study, 2: examine the cyclin E antibody as a prognostic marker for stage I and II breast cancer in a PROSPECTIVE study, 2: examine the cyclin E alterations in samples with the expression of key cell cycle regulators in freshly resected tumor samples, ind 3: develop an immunohistochemical (IHC) assay for specifically detecting the LMW forms of cyclin E in Breast Cancer. We will correlate the cyclin E otherexpression correlates with poor outcome, clinicians can more appropriately tailor aggressive systemic treatment to those at greatest risk for systemic metastases 16. SUBJECT TERMS Prospective study, cell cycle, cyclin E, low molecular weight 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT Nor ABSTRACT Nor PAGES 19a. NAME OF RESPONSIBLE PERSON USAMENC	•					· · · · · · · · · · · · · · · · · · ·
2. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 3. SUPPLEMENTARY NOTES 4. ABSTRACT 4. ABSTRACT 4. ABSTRACT 5. ABSTRACT 5. SUPPLEMENTARY NOTES 4. ABSTRACT 4. ABSTRACT 5. SUBJECT TERMS 5. Stat dysregulation of cyclin E, a positive cell cycle regulator at the G1 to S transition, may affect the biological behavior 5. Stat dysregulation of cyclin E, a positive cell cycle regulator at the G1 to S transition, may affect the biological behavior 5. Stat dysregulation of cyclin E, a positive cell cycle regulator at the G1 to S transition, may affect the biological behavior 5. Stat dysregulation of cyclin E protein and its LMW isoforms was a very strong predictor of breast cancer death 6. Security and its immune-complex formation of uncome in early stage breast cancer. Specifically we will: 6. SECURITY CLASSIFICATION OF: 7. This PAGE 7. This	ort Detrick, Maryla	and 21702-501	2		11.	SPONSOR/MONITOR'S REPORT
A ABSTRACT Aberrations in expression of cyclin E, a positive cell cycle regulator at the G1 to S transition, may affect the biological behavior of breast cancer. In a retrospective analysis of tumor specimens from 395 breast cancer patients, we found that overexpression of the full-length cyclin E protein and its LMW isoforms was a very strong predictor of breast cancer death egardless of whether patients had lymph node-negative disease or lymph node-positive disease (p <0.0001). Our hypothesis s that dysregulation of cyclin E is a powerful prognostic indicator of outcome in early stage breast cancer. Specifically we will: L: use cyclin E antibody as a prognostic marker for stage I and II breast cancer in a PROSPECTIVE study, 2: examine the cyclin E associated activity and its immune-complex formation with key cell cycle regulators in freshly resected tumor samples, and 3: develop an immunohistochemical (IHC) assay for specifically detecting the LMW forms of cyclin E in Breast Cancer. We will correlate the cyclin E alterations in samples with the expression of key cell cycle regulators and clinical biomarkers. If we prospectively confirm cyclin E overexpression correlates with poor outcome, clinicians can more appropriately tailor aggressive systemic treatment to those at greatest risk for systemic metastases H5. SUBJECT TERMS Prospective study, cell cycle, cyclin E, low molecular weight						
A ABSTRACT Aberrations in expression of cyclin E, a positive cell cycle regulator at the G1 to S transition, may affect the biological behavior of breast cancer. In a retrospective analysis of tumor specimens from 395 breast cancer patients, we found that overexpression of the full-length cyclin E protein and its LMW isoforms was a very strong predictor of breast cancer death egardless of whether patients had lymph node-negative disease or lymph node-positive disease (p <0.0001). Our hypothesis is that dysregulation of cyclin E is a powerful prognostic indicator of outcome in early stage breast cancer. Specifically we will: i: use cyclin E antibody as a prognostic marker for stage I and II breast cancer in a PROSPECTIVE study, 2: examine the cyclin E associated activity and its immune-complex formation with key cell cycle regulators in freshly resected tumor samples, and 3: develop an immunohistochemical (IHC) assay for specifically detecting the LMW forms of cyclin E in Breast Cancer. We will correlate the cyclin E alterations in samples with the expression of key cell cycle regulators and clinical biomarkers. If we prospectively confirm cyclin E overexpression correlates with poor outcome, clinicians can more appropriately tailor aggressive systemic treatment to those at greatest risk for systemic metastases 15. SUBJECT TERMS Prospective study, cell cycle, cyclin E, low molecular weight 16. SECURITY CLASSIFICATION OF: 17. LIMITATION 07 ABSTRACT 07 ABSTR						· · · · · · · · · · · · · · · · · · ·
3. SUPPLEMENTARY NOTES 4. ABSTRACT Aberrations in expression of cyclin E, a positive cell cycle regulator at the G1 to S transition, may affect the biological behavior of breast cancer. In a retrospective analysis of tumor specimens from 395 breast cancer patients, we found that overexpression of the full-length cyclin E protein and its LMW isoforms was a very strong predictor of breast cancer death egardless of whether patients had lymph node-negative disease or lymph node-positive disease (p <0.0001). Our hypothesis is that dysregulation of cyclin E is a powerful prognostic indicator of outcome in early stage breast cancer. Specifically we will: I: use cyclin E antibody as a prognostic marker for stage I and II breast cancer in a PROSPECTIVE study, 2: examine the cyclin E associated activity and its immune-complex formation with key cell cycle regulators in freshly resected tumor samples, and 3: develop an immunohistochemical (IHC) assay for specifically detecting the LMW forms of cyclin E in Breast Cancer. We will correlate the cyclin E alterations in samples with the expression of key cell cycle regulators and clinical biomarkers. If we prospectively confirm cyclin E overexpression correlates with poor outcome, clinicians can more appropriately tailor aggressive systemic treatment to those at greatest risk for systemic metastases						•
ABSTRACT Aberrations in expression of cyclin E, a positive cell cycle regulator at the G1 to S transition, may affect the biological behavior of breast cancer. In a retrospective analysis of tumor specimens from 395 breast cancer patients, we found that overexpression of the full-length cyclin E protein and its LMW isoforms was a very strong predictor of breast cancer death egardless of whether patients had lymph node-negative disease or lymph node-positive disease (p <0.0001). Our hypothesis is that dysregulation of cyclin E is a powerful prognostic indicator of outcome in early stage breast cancer. Specifically we will: i: use cyclin E antibody as a prognostic marker for stage I and II breast cancer in a PROSPECTIVE study, 2: examine the cyclin E antibody as a prognostic marker for stage I and II breast cancer in a PROSPECTIVE study, 2: examine the cyclin E associated activity and its immune-complex formation with key cell cycle regulators in freshly resected tumor samples, and 3: develop an immunohistochemical (IHC) assay for specifically detecting the LMW forms of cyclin E in Breast Cancer. We will correlate the cyclin E alterations in samples with the expression of key cell cycle regulators and clinical biomarkers. If we porospectively confirm cyclin E overexpression correlates with poor outcome, clinicians can more appropriately tailor aggressive systemic treatment to those at greatest risk for systemic metastases 15. SUBJECT TERMS Prospective study, cell cycle, cyclin E, low molecular weight 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include aree or of the full-terestical to the cycle area of the study are		·	· · ·	x		· · ·
A ABSTRACT Aberrations in expression of cyclin E, a positive cell cycle regulator at the G1 to S transition, may affect the biological behavior of breast cancer. In a retrospective analysis of tumor specimens from 395 breast cancer patients, we found that overexpression of the full-length cyclin E protein and its LMW isoforms was a very strong predictor of breast cancer death egardless of whether patients had lymph node-negative disease or lymph node-positive disease (p <0.0001). Our hypothesis is that dysregulation of cyclin E is a powerful prognostic indicator of outcome in early stage breast cancer. Specifically we will: : use cyclin E antibody as a prognostic marker for stage I and II breast cancer in a PROSPECTIVE study, 2: examine the cyclin E antibody as a prognostic marker for stage I and II breast cancer in a PROSPECTIVE study, 2: examine the cyclin E associated activity and its immune-complex formation with key cell cycle regulators in freshly resected tumor samples, and 3: develop an immunohistochemical (IHC) assay for specifically detecting the LMW forms of cyclin E in Breast Cancer. We will correlate the cyclin E alterations in samples with the expression of key cell cycle regulators and clinical biomarkers. If we porospectively confirm cyclin E overexpression correlates with poor outcome, clinicians can more appropriately tailor aggressive systemic treatment to those at greatest risk for systemic metastases 15. SUBJECT TERMS Prospective study, cell cycle, cyclin E, low molecular weight 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include aree 19b. TELEPHONE NUMBER (include aree) 19b. TELEPHONE NUMBER 10cm						
Aberrations in expression of cyclin E, a positive cell cycle regulator at the G1 to S transition, may affect the biological behavior of breast cancer. In a retrospective analysis of tumor specimens from 395 breast cancer patients, we found that every pression of the full-length cyclin E protein and its LMW isoforms was a very strong predictor of breast cancer death egardless of whether patients had lymph node-negative disease or lymph node-positive disease (p <0.0001). Our hypothesis is that dysregulation of cyclin E is a powerful prognostic indicator of outcome in early stage breast cancer. Specifically we will:	3. SUPPLEMENTARY	NOTES	······	······		
Aberrations in expression of cyclin E, a positive cell cycle regulator at the G1 to S transition, may affect the biological behavior of breast cancer. In a retrospective analysis of tumor specimens from 395 breast cancer patients, we found that expression of the full-length cyclin E protein and its LMW isoforms was a very strong predictor of breast cancer death egardless of whether patients had lymph node-negative disease or lymph node-positive disease (p <0.0001). Our hypothesis is that dysregulation of cyclin E is a powerful prognostic indicator of outcome in early stage breast cancer. Specifically we will:		·		•		
of breast cancer. In a retrospective analysis of tumor specimens from 395 breast cancer patients, we found that overexpression of the full-length cyclin E protein and its LMW isoforms was a very strong predictor of breast cancer death egardless of whether patients had lymph node-negative disease or lymph node-positive disease (p <0.0001). Our hypothesis	4. ABSTRACT			· · · · · · · · · · · · · · · · · · ·	·····	· · ·
overexpression of the full-length cyclin É protein and its LMW isoforms was a very strong predictor of breast cancer death egardless of whether patients had lymph node-negative disease or lymph node-positive disease (p <0.0001). Our hypothesis						
egardless of whether patients had lymph node-negative disease or lymph node-positive disease (p <0.0001). Our hypothesis s that dysregulation of cyclin E is a powerful prognostic indicator of outcome in early stage breast cancer. Specifically we will: I: use cyclin E antibody as a prognostic marker for stage I and II breast cancer in a PROSPECTIVE study, 2: examine the cyclin E associated activity and its immune-complex formation with key cell cycle regulators in freshly resected tumor samples, and 3: develop an immunohistochemical (IHC) assay for specifically detecting the LMW forms of cyclin E in Breast Cancer. We will correlate the cyclin E alterations in samples with the expression of key cell cycle regulators and clinical biomarkers. If we prospectively confirm cyclin E overexpression correlates with poor outcome, clinicians can more appropriately tailor aggressive systemic treatment to those at greatest risk for systemic metastases 15. SUBJECT TERMS Prospective study, cell cycle, cyclin E, low molecular weight 16. SECURITY CLASSIFICATION OF: a. REPORT b. ABSTRACT c. THIS PAGE 17. LIMITATION 0 ABSTRACT c. THIS PAGE	of breast cancer in					
s that dysregulation of cyclin E is a powerful prognostic indicator of outcome in early stage breast cancer. Specifically we will: I: use cyclin E antibody as a prognostic marker for stage I and II breast cancer in a PROSPECTIVE study, 2: examine the cyclin E associated activity and its immune-complex formation with key cell cycle regulators in freshly resected tumor samples, and 3: develop an immunohistochemical (IHC) assay for specifically detecting the LMW forms of cyclin E in Breast Cancer. We will correlate the cyclin E alterations in samples with the expression of key cell cycle regulators and clinical biomarkers. If we prospectively confirm cyclin E overexpression correlates with poor outcome, clinicians can more appropriately tailor aggressive systemic treatment to those at greatest risk for systemic metastases 15. SUBJECT TERMS Prospective study, cell cycle, cyclin E, low molecular weight 16. SECURITY CLASSIFICATION OF: a. REPORT b. ABSTRACT c. THIS PAGE 17. LIMITATION 0 ABSTRACT c. THIS PAGE 19b. TELEPHONE NUMBER (include area 19b. TELEPHONE NUMBER (include area						
I: use cyclin E antibody as a prognostic marker for stage I and II breast cancer in a PROSPECTIVE study, 2: examine the cyclin E associated activity and its immune-complex formation with key cell cycle regulators in freshly resected tumor samples, and 3: develop an immunohistochemical (IHC) assay for specifically detecting the LMW forms of cyclin E in Breast Cancer. We will correlate the cyclin E alterations in samples with the expression of key cell cycle regulators and clinical biomarkers. If we prospectively confirm cyclin E overexpression correlates with poor outcome, clinicians can more appropriately tailor aggressive systemic treatment to those at greatest risk for systemic metastases 15. SUBJECT TERMS Prospective study, cell cycle, cyclin E, low molecular weight 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF BABSTRACT 18. NUMBER 19a. NAME OF RESPONSIBLE PERSON 19b. TELEPHONE NUMBER (include area	overexpression of t				de-positive d	
cyclin E associated activity and its immune-complex formation with key cell cycle regulators in freshly resected tumor samples, and 3: develop an immunohistochemical (IHC) assay for specifically detecting the LMW forms of cyclin E in Breast Cancer. We will correlate the cyclin E alterations in samples with the expression of key cell cycle regulators and clinical biomarkers. If we prospectively confirm cyclin E overexpression correlates with poor outcome, clinicians can more appropriately tailor aggressive systemic treatment to those at greatest risk for systemic metastases 15. SUBJECT TERMS Prospective study, cell cycle, cyclin E, low molecular weight 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area	overexpression of t egardless of wheth	n of cyclin F is				
and 3: develop an immunohistochemical (IHC) assay for specifically detecting the LMW forms of cyclin E in Breast Cancer. We will correlate the cyclin E alterations in samples with the expression of key cell cycle regulators and clinical biomarkers. If we prospectively confirm cyclin E overexpression correlates with poor outcome, clinicians can more appropriately tailor aggressive systemic treatment to those at greatest risk for systemic metastases 15. SUBJECT TERMS Prospective study, cell cycle, cyclin E, low molecular weight 16. SECURITY CLASSIFICATION OF: a. REPORT b. ABSTRACT c. THIS PAGE U	overexpression of t egardless of wheth s that dysregulatio				in early stage	
will correlate the cyclin E alterations in samples with the expression of key cell cycle regulators and clinical biomarkers. If we prospectively confirm cyclin E overexpression correlates with poor outcome, clinicians can more appropriately tailor aggressive systemic treatment to those at greatest risk for systemic metastases 15. SUBJECT TERMS Prospective study, cell cycle, cyclin E, low molecular weight 16. SECURITY CLASSIFICATION OF: a. REPORT b. ABSTRACT c. THIS PAGE 17. LIMITATION of ABSTRACT b. ABSTRACT c. THIS PAGE 18. NUMBER 19. ABSTRACT 19. ABSTRACT 19. ABSTRACT 19. ABSTRACT 19. ABSTRACT 19. TELEPHONE NUMBER (include area	overexpression of t egardless of wheth s that dysregulatio I: use cyclin E anti	body as a prog	nostic marker for stag	ge I and II breast cance	in early stage er in a PROS	PECTIVE study, 2: examine the
will correlate the cyclin E alterations in samples with the expression of key cell cycle regulators and clinical biomarkers. If we prospectively confirm cyclin E overexpression correlates with poor outcome, clinicians can more appropriately tailor aggressive systemic treatment to those at greatest risk for systemic metastases 15. SUBJECT TERMS Prospective study, cell cycle, cyclin E, low molecular weight 16. SECURITY CLASSIFICATION OF: 17. LIMITATION 18. NUMBER 19a. NAME OF RESPONSIBLE PERSON 0F ABSTRACT 0F ABSTRACT 19b. TELEPHONE NUMBER (include area	overexpression of t egardless of wheth s that dysregulatio I: use cyclin E anti	body as a prog	nostic marker for stag	ge I and II breast cance	in early stage er in a PROS	PECTIVE study, 2: examine the
Systemic treatment to those at greatest risk for systemic metastases 15. SUBJECT TERMS Prospective study, cell cycle, cyclin E, low molecular weight 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area 19b. TELEPHONE NUMBER (include area	overexpression of t egardless of wheth s that dysregulatio I: use cyclin E anti cyclin E associated	body as a prog I activity and its	nostic marker for stag immune-complex fo	ge I and II breast cance rmation with key cell c	in early stage er in a PROS ycle regulator	PECTIVE study, 2: examine the s in freshly resected tumor samples,
15. SUBJECT TERMS Prospective study, cell cycle, cyclin E, low molecular weight 16. SECURITY CLASSIFICATION OF: a. REPORT b. ABSTRACT c. THIS PAGE USAMRMC a. REPORT b. ABSTRACT c. THIS PAGE	overexpression of t egardless of wheth s that dysregulatio I: use cyclin E anti cyclin E associated and 3: develop an i	body as a prog l activity and its immunohistoch	nostic marker for stag s immune-complex fo lemical (IHC) assay fo	ge I and II breast cance rmation with key cell cy or specifically detecting	in early stage er in a PROS ycle regulator g the LMW fo	PECTIVE study, 2: examine the s in freshly resected tumor samples, rms of cyclin E in Breast Cancer. We
Prospective study, cell cycle, cyclin E, low molecular weight 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area 19b. TELEPHONE NUMBER (include area	verexpression of t egardless of wheth s that dysregulatio : use cyclin E anti cyclin E associated and 3: develop an i vill correlate the cy	body as a prog l activity and its immunohistoch /clin E alteratio	nostic marker for stag immune-complex fo emical (IHC) assay fo ns in samples with th	ge I and II breast cance rmation with key cell co or specifically detecting e expression of key ce	in early stage er in a PROS ycle regulator g the LMW fo Il cycle regula	PECTIVE study, 2: examine the s in freshly resected tumor samples rms of cyclin E in Breast Cancer. We ators and clinical biomarkers. If we
Prospective study, cell cycle, cyclin E, low molecular weight 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT A. REPORT I. ABSTRACT I. ABSTRACT	verexpression of t egardless of wheth s that dysregulatio : use cyclin E anti cyclin E associated and 3: develop an i vill correlate the cy prospectively confil	body as a prog l activity and its immunohistoch /clin E alteratio rm cyclin E ove	nostic marker for stag immune-complex fo emical (IHC) assay fo ns in samples with th erexpression correlate	ge I and II breast cance rmation with key cell co or specifically detecting e expression of key ce as with poor outcome, o	in early stage er in a PROS ycle regulator g the LMW fo Il cycle regula	PECTIVE study, 2: examine the s in freshly resected tumor samples rms of cyclin E in Breast Cancer. We ators and clinical biomarkers. If we
A. REPORT D. ABSTRACT C. THIS PAGE OF ABSTRACT OF PAGES USAMRMC	verexpression of t egardless of wheth s that dysregulatio : use cyclin E anti cyclin E associated and 3: develop an i vill correlate the cy prospectively confil systemic treatment	body as a prog I activity and its immunohistoch /clin E alteratio rm cyclin E ove t to those at gre	nostic marker for stag immune-complex fo emical (IHC) assay fo ns in samples with th erexpression correlate	ge I and II breast cance rmation with key cell co or specifically detecting e expression of key ce as with poor outcome, o	in early stage er in a PROS ycle regulator g the LMW fo Il cycle regula	PECTIVE study, 2: examine the s in freshly resected tumor samples, rms of cyclin E in Breast Cancer. We ators and clinical biomarkers. If we
a. REPORT b. ABSTRACT c. THIS PAGE 19b. TELEPHONE NUMBER (include area	overexpression of t egardless of wheth s that dysregulatio I: use cyclin E anti cyclin E associated and 3: develop an i will correlate the cy prospectively confil systemic treatment	body as a prog l activity and its immunohistoch /clin E alteratio rm cyclin E ove t to those at gre	nostic marker for stag immune-complex for emical (IHC) assay for ns in samples with the exerptession correlate eatest risk for systemi	ge I and II breast cance rmation with key cell co or specifically detecting e expression of key ce as with poor outcome, o c metastases	in early stage er in a PROS ycle regulator g the LMW fo Il cycle regula	PECTIVE study, 2: examine the s in freshly resected tumor samples, rms of cyclin E in Breast Cancer. We ators and clinical biomarkers. If we
	verexpression of t egardless of wheth s that dysregulatio : use cyclin E anti cyclin E associated and 3: develop an i will correlate the cy prospectively confil systemic treatment 5. SUBJECT TERMS Prospective study,	body as a prog l activity and its immunohistoch /clin E alteratio rm cyclin E ove t to those at gre cell cycle, cycl	nostic marker for stag immune-complex for emical (IHC) assay for ns in samples with the exerptession correlate eatest risk for systemi	ge I and II breast cance rmation with key cell co or specifically detecting e expression of key ce as with poor outcome, o c metastases reight 17. LIMITATION	in early stage er in a PROS ycle regulator g the LMW fo Il cycle regula clinicians can	PECTIVE study, 2: examine the s in freshly resected tumor samples, rms of cyclin E in Breast Cancer. We ators and clinical biomarkers. If we more appropriately tailor aggressive
	overexpression of t regardless of wheth s that dysregulatio t: use cyclin E anti cyclin E associated and 3: develop an i will correlate the cy prospectively confil systemic treatment 15. SUBJECT TERMS Prospective study, 16. SECURITY CLASS	body as a prog l activity and its immunohistoch yclin E alteratio rm cyclin E ove t to those at gre cell cycle, cycl	nostic marker for stag immune-complex for emical (IHC) assay for ns in samples with the expression correlate eatest risk for systemination in E, low molecular w	ge I and II breast cance rmation with key cell co or specifically detecting e expression of key ce as with poor outcome, o c metastases reight 17. LIMITATION	in early stage er in a PROS ycle regulator g the LMW fo Il cycle regula clinicians can	PECTIVE study, 2: examine the s in freshly resected tumor samples, rms of cyclin E in Breast Cancer. We ators and clinical biomarkers. If we more appropriately tailor aggressive 19a. NAME OF RESPONSIBLE PERSON USAMRMC
	overexpression of t egardless of wheth s that dysregulatio I: use cyclin E anti cyclin E associated and 3: develop an i will correlate the cy prospectively confil systemic treatment I5. SUBJECT TERMS Prospective study, I6. SECURITY CLASS	body as a prog l activity and its immunohistoch /clin E alteratio rm cyclin E ove t to those at gre cell cycle, cycl IFICATION OF: b. ABSTRACT	nostic marker for stag immune-complex for emical (IHC) assay for ns in samples with the exercise of the systemic eatest risk for systemic in E, low molecular w	ge I and II breast cancer rmation with key cell cy or specifically detecting e expression of key ce es with poor outcome, of c metastases reight 17. LIMITATION OF ABSTRACT	in early stage er in a PROS ycle regulator g the LMW fo Il cycle regula clinicians can 18. NUMBER OF PAGES	PECTIVE study, 2: examine the s in freshly resected tumor samples, rms of cyclin E in Breast Cancer. We ators and clinical biomarkers. If we more appropriately tailor aggressive 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area

TABLE OF CONTENTS

Front Cover	page 1
SF 298 Report Documentation Page	page 2
Table of Contents	page 3
Introduction	page 4
Body/Results	.page 7
Conclusions/Discussion	.page 9
References	.page 10

Introduction:

The overall purpose of this 3 year study is to use the altered expression of cyclin E as a prognostic marke for breast cancer.

Human cyclin E was first identified in 1991 through screening of human cDNA libraries for genes that would substitute for G1 cyclin mutations in yeast [1, 2]. Further studies demonstrated that cyclin E levels were periodic during the cell cycle with levels of protein peaking in G1 [3]. This peak in cyclin E levels also correlated with maximum enzymatic function of the cyclin E-cdk2 complex [3]. The critical role of cyclin E in regulating G1 to S transition was confirmed by 2 studies in the mid-1990s. In one study, microinjection of anti-cyclin E antibodies into fibroblasts during G1 resulted in cell cycle arrest [4]. Conversely, in the other study, constitutive overexpression of cyclin E resulted in shortening of the G1 phase, decrease in cell size, and diminished requirements for growth factors [5].

Many studies point to the relevance of cyclin E alterations in breast cancer. The cyclin E gene is amplified in some breast cancer cell lines [6, 7] and we have shown that this amplification can result in as much as a 64-fold overexpression of cyclin E mRNA that is constitutively expressed across all phases of the cell cycle [8, 9]. Examination of the oncogenic potential of cyclin E in transgenic mice under the control of the bovine ß-lactoglobulin promoter, revealed that lactating mammary glands of the transgenic mice overexpressing cyclin E contained regions of hyperplasia and over 10% of the mice developed mammary carcinomas [10]. Lastly, constitutive overexpression of cyclin E (but not cyclin D1 or A) in both immortalized rat embryo fibroblasts and human breast epithelial cells results in chromosomal instability [11]. Collectively, these data provide strong support for the role of cyclin E in breast tumorigenesis. We believe that the most significant cyclin E alteration is the post-translational cleavage of full-length cyclin E into low molecular weight (LMW) forms that are hyperactive compared to the full-

length protein. Some breast cancer cell lines and human breast cancers express up to 5 LMW isoforms of cyclin E (ranging in size from 34 to 49 kDa), in addition to overexpressing the 50 kDa full-length cyclin E protein [6, 12-14]. These LMW forms are unique to tumor cells and correlate with increasing stage and grade of breast cancer [12, 14-16].

Cyclin E as a Prognostic Factor in Breast Cancer

ľ

To test the clinical significance of the LMW forms of cyclin E in breast cancer prognosis, we measured expression of cyclin E in 395 women with primary breast tumors and correlated cyclin E expression with other established prognostic factors and clinical outcome. Cyclin E levels were the most powerful independent predictor for survival in stage I-III breast cancer [17]. In this study cyclin E was evaluated in breast tumors using western blot analysis. Full-length cyclin E, LMW forms, and total cyclin E levels were compared on univariate analysis with standard clinical factors (age, tumor size, nodal status, stage of disease) and biologic markers (estrogen-receptor status, progesterone-receptor status, ploidy, proliferation index, HER-2/neu status, cyclin D1 and cyclin D3). Although multiple clinical, histologic and molecular markers were significantly associated with outcome in the univariate analysis, most lost significance in the multivariate analysis. The LMW cyclin E levels and total cyclin E levels were the most powerful discriminants of overall and disease-free survival in this model and outperformed positive nodal status, stage III-IV disease status and negative estrogen-receptor status. Lymph node status has been the best prognostic factor available for assessing outcomes in women with breast cancer. In this study, cyclin E was a better prognostic indicator than nodal status and even for stage I patients who all had negative lymph nodes, cyclin E was the best indicator of outcome. These results are now being validated in a prospective trial at the M. D. Anderson Cancer Center, which is the topic of this proposal.

Cyclin E and Other Prognostic Markers in Breast Cancer

Numerous molecular markers have emerged over the past decade that may play a role in breast tumorigenesis and prognosis. These factors include estrogen-receptor, progesterone receptor, HER-2/neu and other members of the epidermal growth factor receptor family, cyclins D, E, and B, insulin-like growth factor 1 receptor, matrix metalloproteinases, p53, bcl-2, survivin, cathepsin D, and telomerase activity, to name just a few. These molecular markers frequently perform better in prognostic models than pathologic factors such as S-phase fraction, proliferation indices (Ki67) and mitotic index. The most commonly used markers in clinical practice are ER, PR and HER-2/neu. Patients whose tumors are negative for estrogen receptor have a worse prognosis than those whose tumors are positive for ER and this marker can also be used to select patients who may benefit from hormonal therapy. However, patients with estrogen receptor positive tumors still develop distant metastases and not all ER positive tumors will respond to hormonal therapy.

1

1

The human epidermal growth factor receptor 2 (HER-2/neu) is overexpressed in 25-30% of human breast cancers, suggesting a role for this overexpression in tumorigenesis [18-20]. In most cases, this overexpression is a result of gene amplification. Overexpression of this proto-oncogene in preclinical studies was associated with increased rates of cell growth, tumorigenicity and enhanced metastatic potential when transplanted into nude mice[21, 22]. Preclinical studies demonstrated that treatment of HER-2/neu overexpressing SK-BR-3 breast cancer cells with 4D5 (a murine anti-Her-2/neu antibody) inhibited cell growth [23]. A number of clinical studies have shown that breast cancers that overexpress HER-2/neu have a more aggressive course, higher relapse rate and mortality rate [19], a finding that was most pronounced in node positive patients [20, 24, 25]. Trastuzumab (Herceptin, Genentech BioOncology) was recently approved by the FDA for the treatment of HER-2/neu positive breast cancer. Trastuzumab is a humanized murine monoclonal IgG1 antibody that binds a juxtamembrane epitope in the ectodomain of HER-2/neu. Identification of HER-2/neu gene

amplification can be important in prognosis and in selecting patients for therapy with trastuzumab.

When the assessment of cyclin E was compared with both molecular markers and pathologic factors in breast tumors, all of these provided some degree of prognostic value on univariate analysis [17]. However, cyclin E was the most powerful discriminant between good and bad prognosis cohorts. When compared with the cell cycle regulators, cyclin D1 and D3, the 5-year disease-specific survival was significantly longer among patients with low levels of LMW, full-length or total cyclin E as compared with patients whose tumors had high levels of these proteins (p<0.001, log rank test). Levels (high or low) of cyclin D1 and cyclin D3 were also associated with poor disease-specific and overall survival, but less striking than those for cyclin E. Cyclin D1, cyclin D3 and HER-2/neu did not reach statistical significance when subjected to a multivariate analysis.

<u>Results</u>

1

The scope of our Statement of Work for the year 2 of the study was to continue Aim 1: Aim 1: To use cyclin E antibody as a prognostic marker for stage I and II breast cancer in a PROSPECTIVE study (months 1-36)

A. Freshly resected breast tissue samples (normal adjacent and tumor) from 260 patients diagnosed with stage I and Stage II breast tumors will be collected; RNA, DNA and protein extracted. (months 1-24).

During the year 2 of the study we enrolled 389 patients on the study. From these 314 patients, 75 patients had neoadjuvant chemotherapy and were excluded from further analysis. Of the remaining 314 patients, 260 stage I/II patients had tissue available, where whole cell lysates were prepared from the biopsy material and subjected them to western blot analysis as follows:

0.1 gram of each matched tissue (normal adjacent tissue and breast cancer tissue obtained from the same patient) were obtained within 30-45 minutes after excision of the tumor. We extracted protein homogenates from all samples. For whole cell lysate preparation, the tissue specimen were added to one volume of sonication buffer containing a cocktail of protease and phosphatase inhibitors in a low salt buffer, minced and homogenized in a micro-mincer and sonicated at 4°C using a cup-horn adapter to eliminate probe intrusion. Homogenates were then centrifuged at 100,000 X g for 45 minutes at 4°C. The supernatants were aliquoted, and stored at -70°C and subjected to western blot analysis as described [26, 27]. The protein extracts from the 220 tumor specimen (and their corresponding normal adjacent tissue) collected thus far were subjected to Western blot analysis and the expression of cyclin E is being compared and correlated with other known prognostic markers examined in the same samples. Figure 1 depicts the summary of this study thus far:

Figure 1: Summary of tissue collection for the cyclin E study.

75 patients neoadjuvant chemotherapy excluded from analysis

> 220 patients western blot analysis scompleted

31 patients (14%)

For each of the samples analyzed for western blot, we also performed kinase assays to examine the activity of cyclin E.

On the clinical side we obtained final IRB approal from your office on the study. The approval came on 1/18/05 and presented as figure 2.

Figure 2:

;

:

A copy of the IRB approval memo from the Army.



To: "Duchesneau, Caryn L Ms USAMRMC" (caryn.duchesneau@us.army.mil) **: 01718/05 10:43 FM

Laspe, Danny L Mr USAMRAA" (daray.laspe@us.army.mil)

"Christian, Carole B Dr USAMR1dC" «carole.christiangus army mil>, «mahassett@mdanderson.org», Ukkeyomangmdanderson.org», "Brosch, Laura R DOL USAMRMC" «laura broschigus army.mil>, "Duchesneau,

Subject: A-11666 Continuing Review Acceptance (Proposal No. BC010060, Award No. DAMD17-02-1-0452)

SUBJECT: Continuing Review for Protocol, "Cyclin E, a Powerful Predictor of Survival in Breast Cancer - A Prospective Study", Submitted by Khandan Keyomami, PhD, University of Texas, MD Anderson Cancer Center, Houston, TX, Proposal No. BC010080, Award No. DAMD17-02-1-0452, H3RRB Log No. A-11686

1. The continuing review report for this study was reserved in this office on 3 January 2005. The report was approved by the MD Anderson Cancer Center (MDACC) IRD on 1 December 2004.

2. There are no outstanding human subjects protection issues to be resolved. The study remains no greator than minimal risk. The continuing review report is accepted.

3. Any additional protocol modifications (including but not limited to changes in the recruitment materials or procedures, the principal investigator, inclusion/exclusion criteria, number of subjects to t enrolled, study sites, or procedures) must be submitted as a written amendment for HSRRB reviewed an approved the modifications also must be submitted.

4. In accordance with 32 CFR 219, a copy of the next continuing review report approved by the MDACC (RB must be submitted to this office as soon as possible after approval is received. It appears that the next continuing review report is due to the MDACC IRB no later than 1 December 2005.

S. Use of the Volunteer Registry Data sheet is not required for this study.

8. Please keep the Use of Human Subjects Clause and the Use of Anatomical Substances Clause in the Assistance Agreement for this project.

7. Point of contact (POC) for this action is Donna S. Ferrandino, PhD at 301-619-6237.

CARYN L. DUCHESNEAU, CIP Vice Acting Chaix, Human Subjects Research Review Board

Note: The official signed copy of this approval is housed with the pretocol file at the Office of Research Protections, 504 Scott Street, Fort Detrick, MD, 21702. Signed copies will be provided upon request.

Conclusions/Future Goal

We have completed our goals for the first 2 years of this study which was to accrue 260 patients and subject the lysates to western blot analysis with cyclin E and other biomarkers

Our goal for the coming year is to develop an Immunohistochemical (IHC) assay fro specificially

detecting the LMW forms of cyclin E in breast cancer.

References:

1. Koff, A., et al., *Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family.* Cell, 1991. **66**(6): p. 1217-28.

 Lew, D.J., V. Dulic, and S.I. Reed, Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast. Cell, 1991. 66(6): p. 1197-206.

ċ

1

- 3. Koff, A., et al., *Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle.* Science, 1992. **257**: p. 1689-1694.
- 4. Ohtsubo, M., et al., *Human cyclin E, a nuclear protein essential for the G1-to-S phase transition.*Mol Cell Biol, 1995. **15**(5): p. 2612-24.
- Ohtsubo, M. and J.M. Roberts, *Cyclin-dependent regulation of G1 in mammalian fibroblasts*.
 Science, 1993. **259**: p. 1908-1912.
- Keyomarsi, K. and A. Pardee, *Redundant cyclin overexpression and gene amplification in breast cancer cells.* Proc Natl Acad Sci USA, 1993. 90: p. 1112-1116.
- Buckley, M.F., et al., *Expression and amplification of cyclin genes in human breast cancer.* Oncogene, 1993. 8: p. 2127-2133.
- Sgambato, A., et al., Effects of cyclin E overexpression on cell growth and response to transforming growth factor ß depend on cell context and p27kip1 expression. Cell Growth Diff, 1997. 8: p. 393-405.
- Keyomarsi, K., et al., *Deregulation of cyclin E in breast cancer*. Oncogene, 1995. **11**(5): p. 941 50.
- 10. Bortner, D.M. and M.P. Rosenberg, *Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E.* Mol Cell Biol, 1997. **17**(1): p. 453-9.
- Spruck, C.H., K.A. Won, and S.I. Reed, *Deregulated cyclin E induces chromosome instability*. Nature, 1999. **401**(6750): p. 297-300.
- 12. Keyomarsi, K., et al., *Cyclin E, a potential prognostic marker for breast cancer.* Cancer Res, 1994. 54(2): p. 380-5.
- 13. Keyomarsi, K. and T.W. Herliczek, *The role of cyclin E in cell proliferation, development and cancer.* Prog Cell Cycle Res, 1997. **3**: p. 171-91.

14. Nielsen, N.H., et al., *Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status.* Br J Canc, 1996. **74**: p. 874-880.

•

1

- 15. Wang, Q.-S., et al., Overexpression of cyclin D1 and cyclin E in N-nitrosomethylbenzylamineinduced rate exophageal tumorigenesis. Cacinogenesis, 1996. **17**: p. 1583-1588.
- Scuderi, R., et al., Cyclin E overexpression in relapsed adult acute lymphoblastic leukemias of B-cell lineage. Blood, 1996. 8: p. 3360-3367.
- 17. Keyomarsi, K., et al., Cyclin E and survival in patients with breast cancer. N Engl J Med, 2002.
 347(20): p. 1566-75.
- 18. Slamon, D.J., et al., *Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.* Science, 1987. **235**: p. 177-182.
- 19. Slamon, D.J., et al., *Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.* Science, 1989. **244**(4905): p. 707-12.
- 20. Hynes, N.E., *Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy.* Semin Cancer Biol, 1993. **4**(1): p. 19-26.
- 21. Chazin, V.R., et al., *Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor.* Oncogene, 1992. **7**(9): p. 1859-66.
- 22. Benz, C.C., et al., *Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu.* Breast Cancer Res Treat, 1993. **24**(2): p. 85-95.
- 23. Lewis, G.D., et al., *Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies.* Cancer Immunol Immunother, 1993. **37**(4): p. 255-63.
- Press, M.F., et al., *HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.* J Clin Oncol, 1997. **15**(8): p. 2894-904.

25. Ravdin, P.M. and G.C. Chamness, *The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review.* Gene, 1995. **159**(1): p. 19-27.

^ ر

- 26. Chen, X., et al., Activation of the estrogen-signaling pathway by p21(WAF1/CIP1) in estrogen receptor-negative breast cancer cells. J Natl Cancer Inst, 2000. **92**(17): p. 1403-13.
- 27. Keyomarsi, K., et al., *Cyclin E, a Potential Prognostic Marker for Breast Cancer.* Cancer Res., 1994. **54**: p. 380-385.